Multimodal treatment of perianal fistulas in Crohn's disease: Seton versus anti-TNF versus advancement plasty (PISA): Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  de Groof, E Joline ^a   Buskens, Christianne J ^a   Ponsioen, Cyriel Y ^a   Dijkgraaf, Marcel G W ^a   D'Haens, Geert R A M ^a   Srivastava, Nidhi ^b   van Acker, Gijs J D ^b   Jansen, Jeroen M ^c   Gerhards, Michael F ^c   Dijkstra, Gerard ^d   Lange, Johan F M ^d   Witteman, Ben J M ^e   Kruyt, Philip M ^e   Pronk, Apollo ^f   van Tuyl, Sebastiaan A C ^f   Bodelier, Alexander ^g   Crolla, Rogier M P H ^g   West, Rachel L ^h   Vrijland, Wietske W ^h   Consten, Esther C J ⁱ   Brink, Menno A ⁱ   Tuynman, Jurriaan B ^j   de Boer, Nanne K H ^j   Breukink, Stephanie O ^k   Pierik, Marieke J ^k   Oldenburg, Bas ^l   van der Meulen, Andrea E ^m   Bonsing, Bert A ^m   Spinelli, Antonino ⁿ   Danese, Silvio ⁿ   Sacchi, Matteo ⁿ   Warusavitarne, Janindra ^o   Hart, Ailsa ^o   Yassin, Nuha A ^o   Kennelly, Rory P ^p   Cullen, Garret J ^p   Winter, Desmond C ^p   Hawthorne, A Barney ^q   Torkington, Jared ^q   Bemelman, Willem A ^a   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e GELDERSE VALLEI HOSPITAL   (Netherlands)

^f DEPARTMENT OF SURGERY   (Netherlands)

^g AMPHIA HOSPITAL   (Netherlands)

^h SINT FRANCISCUS GASTHUIS   (Netherlands)

ⁱ MEANDER MEDICAL CENTER   (Netherlands)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^o ST MARK S HOSPITAL   (United Kingdom)

^p St Vincent's Healthcare Group   (Ireland)

^q Spire Cardiff Hospital   (United Kingdom)

more..

Author keywords

Advancement plasty; Anti TNF; Cost effectiveness; Crohn's disease; Perianal fistula; Quality of life; Seton

Indexed keywords

ADALIMUMAB; INFLIXIMAB; MERCAPTOPURINE; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR;

ADULT; ANOPLASTY; ANUS FISTULA; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; DEVICE REMOVAL; DIGESTIVE IMPLANT; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REOPERATION; SCORING SYSTEM; SETON; SURGICAL DRAINAGE; TREATMENT DURATION; TREATMENT OUTCOME; ABDOMINAL SURGERY; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRAINAGE; ECONOMICS; EUROPE; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PROCEDURES; QUESTIONNAIRE; RECTAL FISTULA; TIME FACTOR;

6-MERCAPTOPURINE; ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; CROHN DISEASE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DRAINAGE; DRUG THERAPY, COMBINATION; EUROPE; GASTROINTESTINAL AGENTS; HEALTH CARE COSTS; HUMANS; MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; RECTAL FISTULA; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939515533     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0831-x     Document Type: Article

References (27)

1. Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut. 1980;21:525-7.
2. Vigano C, Losco A, Caprioli F, Basilisco G. Incidence and clinical outcomes of intersphincteric abscesses diagnosed by anal ultrasonography in patients with Crohn's disease. Inflamm Bowel Dis. 2011;17:2102-8.
3. Buchanan GN, Owen HA, Torkington J, Lunniss PJ, Nicholls RJ, Cohen CR. Long-term outcome following loose-seton technique for external sphincter preservation in complex anal fistula. Br J Surg. 2004;91:476-80.
4. Tanaka S, Matsuo K, Sasaki T, Nakano M, Sakai K, Beppu R, et al. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed? Hepatogastroenterology. 2010;57:3-7.
5. Soltani A, Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn's fistula-in-ano. Dis Colon Rectum. 2010;53:486-95.
6. Osterman MT, Lichtenstein GR. Infliximab in fistulizing Crohn's disease. Gastroenterol Clin North Am. 2006;35:795-820.
7. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-405.
8. Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32:1228-39.
9. Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001;15:1639-46.
10. Ardizzone S, Colombo E, Maconi G, Bollani S, Manzionna G, Petrone MC, et al. Infliximab in treatment of Crohn's disease: the Milan experience. Dig Liver Dis. 2002;34:411-8.
11. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum. 2002;45:771-5.
12. Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis. 2005;37:577-83.
13. Miheller P, Lakatos PL, Horvath G, Molnar T, Szamosi T, Czegledi Z, et al. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study. BMC Gastroenterol. 2009;9:66.
14. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-9.
15. Sands BE, Blank MA, Diamond RH, Barrett JP, van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006;23:1127-36.
16. Van AG, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98:332-9.
17. Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd. 2005;149:1574-8.
18. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-108.
19. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health. 2007;10:336-47.
20. Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2013;63:292-9.
21. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-95.
22. Van AG, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De VM, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010;4:63-101.
23. Morrison JG, Gathright Jr JB, Ray JE, Ferrari BT, Hicks TC, Timmcke AE. Surgical management of anorectal fistulas in Crohn's disease. Dis Colon Rectum. 1989;32:492-6.
24. Williams JG, Rothenberger DA, Nemer FD, Goldberg SM. Fistula-in-ano in Crohn's disease. Results of aggressive surgical treatment. Dis Colon Rectum. 1991;34:378-84.
25. Scott HJ, Northover JM. Evaluation of surgery for perianal Crohn's fistulas. Dis Colon Rectum. 1996;39:1039-43.
26. Takesue Y, Ohge H, Yokoyama T, Murakami Y, Imamura Y, Sueda T. Long-term results of seton drainage on complex anal fistulae in patients with Crohn's disease. J Gastroenterol. 2002;37:912-5.
27. Chung W, Ko D, Sun C, Raval MJ, Brown CJ, Phang PT. Outcomes of anal fistula surgery in patients with inflammatory bowel disease. Am J Surg. 2010;199:609-13.